Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission

Psychiatria Danubina

Volumn 24, Issue 2, 2012, Pages 159-166

  Morozova, Margarita A ^a   Beniashvili, Allan G ^a   Lepilkina, Taisiya A ^a   Rupchev, Georgiy E ^a  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

Author keywords

Add on treatment; Cognitive dysfunction; Dimebon; Schizophrenia

Indexed keywords

DIMEBON; PLACEBO; RISPERIDONE; INDOLE DERIVATIVE; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

ABNORMAL INVOLUNTARY RATING SCALE; ACUTE PSYCHOSIS; ADD ON THERAPY; ADULT; ARTICLE; ATTENTION; BARNES AKATHISIA SCALE; BENTON VISUAL RETENTION TEST; CALGARY DEPRESSION RATING SCALE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EXECUTIVE FUNCTION; HUMAN; MALE; MENTAL PATIENT; MOTOR COORDINATION; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PROOF ASSAY OF BOURDOHN; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIMPSON ANGUS SCALE FOR EXTRAPYRAMIDAL SYMPTOMS; TOWER OF LONDON DREXEL UNIVERSITY; TREATMENT RESPONSE; WECHSLER INTELLIGENCE SCALE; WECHSLER MEMORY SCALE; WISCONSIN CARD SORTING TEST; WORKING MEMORY; ACUTE DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; RISPERIDONE; SCHIZOPHRENIA, PARANOID; SEVERITY OF ILLNESS INDEX;

EID: 84864881933     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Addington D, Addington J & Schissel B: A depression rating scale for schizophrenics. Schizophr Res 1990; 3:247-51.
2. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW et al.: Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010; 13:1021-33.
3. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V et al.: Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001; 939:425-35.
4. Bachurin SO, Ustyugov AA, Peters O, Shelkovnikova TA, Bukhman VL & Ninkina NN: Blockade of proteinopathic neurodegenerative process as a new effect of neuroprotectors and cognitive enhancers [In Russian]. Reports of the Russian Academy of Sciences 2009; 428:262-65.
5. Barak S & Weiner I: Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacol Biochem Behav 2011; 99:164-89.
6. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-76.
7. Culbertson WC & Zillmer EA: The Tower of London, Drexel University, research version: Examiner's manual. Multi-Health Systems, New York, 1999.
8. Dupuis DS, Mannoury la Cour C, Chaput C, Verrièle L, Lavielle G, Millan MJ: Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alphas. Eur J Pharmacol 2008; 588:170-7.
9. Faber G, van Gool AR, Smid HG, Wiersma D & van den Bosch RJ: Typical and atypical antipsychotics: Is there a difference in their influence on neurocognition? Tijdschr Psychiatr 2011; 53:107-17.
10. Filimonenko Yu & Timofeyev Yu: Wechsler Adult Intelligence Scale. User manual [In Russian]. Imaton, Sankt-Peterburg, 2000.
11. Fone KC: An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 2008; 55:1015-22.
12. Guy W: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Washington, DC, 1976.
13. Heaton RK, Chelune GJ, Talley JL, Kay GG & Curtiss G: Wisconsin Card Sorting Test manual: Revised and expanded. Psychological Assessment Resources, Odessa, FL, 1993.
14. Houthoofd SA, Morrens M, Sabbe BG: Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther 2008; 30:1565-89.
15. Ibrahim HM & Tamminga CA: Schizophrenia: treatment targets beyond monoamine systems. Annu Rev Pharmacol Toxicol 2011; 51:189-209.
16. Jones RW: Dimebon disappointment. Alzheimers Res Ther 2010; 2:25.
17. Kane JM & Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71:1115-24.
18. Kay SR, Fiszbein A & Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-76.
19. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM et al.: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64:633-47.
20. Laruelle M, Abi-Dargham A, Gil R, Kegeles L & Innis R: Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999; 46:56-72.
21. Meltzer HY, Massey BW: The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011; 11:59-67.
22. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25:233-55.
23. Mitchell ES, Neumaier JF: 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005;108:320-33.
24. Mitchell ES, Neumaier JF: 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or Scopolamine. Pharmacol Biochem Behav 2008; 88:291-8.
25. Nikiforuk A, Kos T, Rafa D, Behl B, Bespalov A, Popik P: Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility inglycine/NMDA receptor-dependent manner. Neuropharmacology 2011; 61:262-7.
26. Pratt JA, Winchester C, Egerton A, Cochran SM & Morris BJ: Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 2008; 153(S1):465-70.
27. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM: Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 2010; 24:303-17.
28. Rossé G & Schaffhauser H: 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem 2010; 10:207-21.
29. Rubeša G, Gudelj L & Kubinska N: Etiology of schizophrenia and therapeutic options. Psychiatr Danub 2011; 23: 308-315.
30. Rubinstein SYa: Experimental methods of pathological psychology [In Russian]. Meditsina, Moscow, 1970.
31. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA et al.: Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 2009; 78:1035-42.
32. Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG et al.: Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis 2011; 8: 430-7.
33. Simpson GM & Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-9.
34. Sivan AB: Benton Visual Retention Test: Fifth Edition. Psychological Corporation, San Antonio, TX, 1992.
35. Soboleva TV: Use of Proof Assay of Bourdohn-Anfimov for vocational guidance. User manual [In Russian]. Tsentr "Resurs", Yaroslavl, 1999.
36. Stip E: Cognition, schizophrenia and the effect of antipsychotics. Encephale 2006; 32(3 Pt 1):341-50.
37. Šoštarić M & Zalar B: The overlap of cognitive impairment in depression and schizophrenia: a comparative study. Psychiatr Danub 2011; 23: 251-256.
38. Tiplady B: Continuous attention: Rationale and discriminant validation of a test designed for use in psychopharmacology. Behav Res Methods 1992; 24:16-21.
39. Vignisse J, Steinbusch HW, Bolkunov A, Nunes J, Santos AI, Grandfils C et al.: Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:510-22.
40. Wallace TL, Porter RH: Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011; 82:891-903.
41. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M et al.: Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 2011; 6:7.
42. Webster SJ, Wilson CA, Lee CH, Mohler EG, Terry AV Jr & Buccafusco JJ: The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys. Br J Pharmacol 2011; 164:970-8.
43. Wechsler DA: Standartized memory scale for clinical use. J Psychol 1945; 19:87-95.
44. Yamashita M, Nonaka T, Kametani F, Arai T, Akiyama H, Buchman VL et al.: Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS letters 2009; 583:2419-24.